VivaVision Biotech Reports Topline Results from P-II Study of VVN461 for Post-Operative Inflammation Following Cataract Surgery
Shots:
- The P-II trial assessed VVN461 (1.0% & 0.5%) vs vehicle for post-cataract surgery inflammation (n=91), who underwent routine unilateral cataract extraction by phacoemulsification and lens replacement (CELR)
- Study, at D14, showed ACC Grade 0 in 60% & 53.3% vs 19.4% at D14, significantly reduced anterior chamber flare (ACF), ocular pain & effects seen as early as D3. 4/61 VVN461 patients required rescue medication vs 15/30 in the vehicle, highlighting faster healing and improved comfort
- VVN461 (a non-steroidal dual JAK1/TYK2 immunomodulator) showed a low rate of mild AEs, vs. the vehicle, verifying its safety. VivaVision is also testing VVN461 in P-II trials for non-infectious anterior uveitis in China
Ref: Globe Newswire | Image: VivaVision Biotech
Related News:- Eli Lilly Reports Results from the P-IIIb (SURMOUNT-5) Trial of Zepbound (Tirzepatide) in Obese Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
